Originally published on YouTube on 17 February 2026.
Original video: https://www.youtube.com/watch?v=ayi3qDYeYvo

Free guide: The APOE4 Metabolic Guide
https://thephoenix.community/guides/metabolic-guide

As an APOE4/4 carrier, I have spent years researching and experimenting with ketogenic approaches. I compare the clinical trials, explain the differences between MCTs, and walk through my cycling approach and a framework for adapting ketosis to APOE4.

RESOURCES
Apply to join Phoenix: https://apoe4.link/Keto
Essential APOE4 Guide: https://apoe4.link/KetoG
Weekly Newsletter: https://apoe4.link/KetoN

CHAPTERS
00:00 Introduction
00:39 The Brain Energy Crisis
02:20 Why Generic Keto Fails APOE4 Carriers
05:57 APOE4-Specific Modifications
07:52 The Cycling Approach - When to Use Ketosis
11:34 Practical Application
13:53 Key Takeaways
15:44 Conclusion

ORIGINAL LINKS AND REFERENCES
AC-1202 Trial (Henderson et al., 2009): https://pmc.ncbi.nlm.nih.gov/articles/PMC2731764/
BENEFIC Trial (Fortier et al., 2021): https://pmc.ncbi.nlm.nih.gov/articles/PMC8048678/
MCT Ketogenic Effects (Lin et al., 2021): https://pmc.ncbi.nlm.nih.gov/articles/PMC8650700/
Brain Ketone Review (Cunnane et al., 2016): https://pmc.ncbi.nlm.nih.gov/articles/PMC4937039/
APOE4 Neuroimaging (Brandon et al., 2018): https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2018.00180/full
APOE4+ Case Study (Morrill & Gibas, 2019): https://pubmed.ncbi.nlm.nih.gov/31336463/
Ketones & Neurodegeneration (Jensen et al., 2020): https://pmc.ncbi.nlm.nih.gov/articles/PMC7699472/
Exogenous Ketones (Stubbs et al., 2017): https://pmc.ncbi.nlm.nih.gov/articles/PMC5670148/
Keto & Athletes (McSwiney et al., 2019): https://pmc.ncbi.nlm.nih.gov/articles/PMC6863116/
Keto & Performance 2023 (Borszcz et al., 2023): https://pubmed.ncbi.nlm.nih.gov/37144460/
APOE4 & Saturated Fat (Griffin et al., 2018): https://pmc.ncbi.nlm.nih.gov/articles/PMC6213759/
Ketosis & Cognition Review (Altayyar et al., 2022): https://pmc.ncbi.nlm.nih.gov/articles/PMC8840718/

Two copies of APOE4. Does every memory lapse mean something, and would more testing help?
Dr. Gayatri Devi explains why she starts with a cognitive baseline, not constant self-checking.

Dr. Devi directs Park Avenue Neurology in New York and is Clinical Professor of Neurology and Psychiatry at the Zucker School of Medicine at Hofstra/Northwell.

I went in with concerns Phoenix members had raised about memory lapses and testing before symptoms. I did not ask the submitted questions on camera. Several of those concerns still came up.

WANT YOUR QUESTION IN THE NEXT INTERVIEW?

Members can submit questions before future interviews. Not every question fits. Phoenix also helps you build your personal protocol, review your own blood tests and find support from other carriers.
Apply to join Phoenix: https://apoe4.link/GayatriQnA1

RESOURCES
→ Brain Biomarker Guide: https://apoe4.link/GayatriQnA1G
→ Free newsletter: https://apoe4.link/GayatriQnA1N
→ Free Clinical Trial Engine: https://apoe4.link/GayatriQnA1C

A NOTE ON WHAT THIS IS

Educational, not medical advice or a product endorsement. Take this to your own clinician. APOE4 is a risk factor, not a diagnosis.

KEY TAKEAWAYS
1. A useful baseline measures more than memory. Language, visual-spatial skills and switching tasks also matter. An age-average score may not reflect your own earlier ability.
2. Repeating tests can improve test familiarity. Dr. Devi tells her patients to leave at least a year between routine assessments. This is not a rule to delay care for new symptoms.
3. A positive p-tau217 result needs context. She discusses whether amyloid is present, not a person's odds of developing dementia.
4. She notes that most people in their 80s with amyloid are cognitively intact. That does not mean someone will never develop symptoms. Her amyloid case series is unpublished.
5. Her priorities include aerobic exercise, blood vessel health, sleep and stress. Her more proactive views on scans and treatment before symptoms go beyond the guidance and trial evidence she describes.

QUESTIONS FOR YOUR CLINICIAN
What would this test measure? How would you interpret it for someone like me? What would change after a positive, negative or unclear result?
These are discussion prompts, not a testing or treatment protocol.

Full sources and limits are in the original YouTube description.

WHAT WE COVER

00:00 Teaser
01:10 Why a second APOE4 copy matters
02:34 What two copies of APOE4 means, and why age at discovery matters
05:22 What a proper baseline test includes
07:42 Practice effect: how often to retest
08:54 Biomarkers vs. real risk: why plaques don't always mean dementia
14:41 How reliable is the P-tau217 blood test?
16:01 Handling the anxiety: sleep and other no-brainer interventions
17:58 Amyloid scans for people without symptoms
20:08 The amyloid hypothesis and anti-amyloid drugs
24:17 ARIA brain bleed risk and slow dosing
26:48 Final advice from Dr. Devi
28:30 Outro: Kevin's three takeaways

Originally published on YouTube on 25 February 2026.
Original video: https://www.youtube.com/watch?v=XnRBrxA0Z_U

Free guide: The APOE4 Exercise Protocol
https://thephoenix.community/guides/exercise-protocol

I explain Zone 2 training for APOE4 carriers: how the MAF formula estimates a heart-rate range, how to use the talk test, what to track and how to combine aerobic training with higher-intensity exercise. The episode includes a sample training week and the research behind the approach.

RESOURCES
Apply to join Phoenix: https://apoe4.link/Zone2
Essential APOE4 Guide: https://apoe4.link/Zone2G
Weekly Newsletter: https://apoe4.link/Zone2N

CHAPTERS
00:00 Introduction
02:06 Why Zone 2 Matters for APOE4 Brains
05:07 Calculating Your Zone 2 Heart Rate
05:40 MAF Formula Calculation
10:04 Tracking Methods and Weekly Protocol
11:56 Why You Need HIIT Too
13:47 Key Takeaways
15:22 Conclusion

ORIGINAL LINKS AND REFERENCES
- Erickson et al. 2011 - Aerobic exercise increases hippocampal volume by 2% https://pubmed.ncbi.nlm.nih.gov/21282661/
- Kaufman et al. 2021 - APOE4 carriers show greater blood flow improvement from exercise https://pmc.ncbi.nlm.nih.gov/articles/PMC8327103/
- De la Rosa et al. 2020 - Meta-analysis: 45% AD risk reduction from regular exercise https://pmc.ncbi.nlm.nih.gov/articles/PMC7498620/
- Tokgoz & Claassen 2021 - Exercise as treatment for APOE4 carriers (systematic review) https://pmc.ncbi.nlm.nih.gov/articles/PMC8126521/
- FINGER Trial - Lifestyle interventions benefit APOE4 carriers MORE https://www.alzdiscovery.org/cognitive-vitality/blog/healthy-lifestyle-changes-may-benefit-cognition-in-older-people-with-apoe4
- Hu et al. 2021 - HIIT stimulates BDNF expression in hippocampus https://pmc.ncbi.nlm.nih.gov/articles/PMC7946986/
- Park et al. 2021 - High-intensity exercise and hippocampal mitochondrial biogenesis https://pmc.ncbi.nlm.nih.gov/articles/PMC8481603/